Low monocytes shows a huge improvement and under65 is significant.
I don’t think the market fully appreciates these results and the monetary potential. Everyone is looking for the silver bullet, when the reality is different bullets for different patient groups.
At a minimum, if Efti increases life expectancy by nearly two years in 20% of mbc patients and providing better quality of life then it’s a BLOCKBUSTER drug. No ifs-or buts.
And that is only scratching the surface of Efti potential.
I’ll be referring to Efti as a blockbuster in the making from now on.
Ann: Final Phase IIb AIPAC clinical trial results for Efti in MBC, page-7
-
- There are more pages in this discussion • 102 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.040(11.9%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 33.0¢ | 28.0¢ | $7.278M | 23.75M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 53192 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 41048 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |